Microcephaly, Fanconi Anemia and Praxial Disorders (MicroFancII)
Primary Purpose
Fanconi Anemia
Status
Withdrawn
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
MRI of the hand and forearm,
Sponsored by
About this trial
This is an interventional other trial for Fanconi Anemia
Eligibility Criteria
Inclusion Criteria:
Patients with Fanconi Anemia defined according to two of the following diagnostic criteria already included in the MicroFanc study:
- Chromosome breakage test after exposure to an alkylating agent (mitomycin) on peripheral blood lymphocytes.
- FancD2 test on lymphocytes or fibroblasts
- sensitivity of fibroblasts to mitomycin
- mutation in one of the FANC complementation genes (A, B, C, D1, D2, E, F, G, I, J, L, M, N)
- Non-transplanted patients or patients at a distance from CSH transplant (>3 years)
- Age ≥5 years of age at inclusion (minimum age of accessibility for neuropsychological tests and no need for sedation for MRI)
Exclusion Criteria:
Subjects for whom both parents have not agreed to participate in the research, or for whom MRI is contraindicated.
Sites / Locations
- Robert Drbré Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Minor patients with Fanconi anemia
Minor controls
Arm Description
MRI of hands and forearm, neuropsychological and neuromotor tests
MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation
Outcomes
Primary Outcome Measures
measurement of fine motor praxia
Secondary Outcome Measures
Full Information
NCT ID
NCT04656171
First Posted
November 5, 2020
Last Updated
February 2, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT04656171
Brief Title
Microcephaly, Fanconi Anemia and Praxial Disorders
Acronym
MicroFancII
Official Title
Microcephaly, Fanconi Anemia and Praxial Disorders
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Withdrawn
Why Stopped
No financement AFAM
Study Start Date
January 30, 2023 (Actual)
Primary Completion Date
January 30, 2023 (Actual)
Study Completion Date
January 30, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Fanconi Anemia (FA) is mentioned in children with congenital malformations including kidney, hart and skeletal malformations (absence or abnormal thumb or forearm), and bone marrow failure or myelodysplasia with a progressive onset in childhood or adulthood. No study has focused on microcephaly, a reduction in brain volume, which is present in 20% of children, and its consequences on cognitive and structural level of the brain. Since 2014, Robert-Debré's team has been interested in this functional cognitive and neuroanatomical approach trough a National PHRC. Preliminary results carried out on 12 children show that their intellectual efficiency was in the normal range for age. However, we noticed a significant difference between abilities in comprehension and verbal reasoning corresponding to what is expected for age, and the sensorimotor skills or fine motor praxia significantly reduced. These difficulties, graphically penalizing for these children, are not always explained by a skeletal malformation of the upper limb, suggesting that musculo-tendinous anomalies may be associated. The objectives of our project are: 1) to identify upper limb musculo-tendinous abnormalities and their functional consequences, 2) to determine if these abnormalities could influence the somatosensory representation of the upper limb at the cerebral cortical level. This project should help us to better understand the fine motor disabilities or developmental coordination disorder of these children, which penalize their learning, and provide them with adapted solutions.
Detailed Description
Our hypothesis is that children with FA present a developmental dyspraxia. This condition is very penalizing for children especially regarding graphic tasks, handwriting, whether or not they have skeletal malformations of the upper limbs. Consequences are fatigue because of energy expended trying to execute fine motor movements correctly.
Main objective:
To identify gesture dyspraxia in order to propose a targeted rehabilitation leading to national recommendations.
Main Evaluation Criteria :
measurement of fine motor praxia
quantification of dyspraxia
Secondary Objectives :
To identify the musculoskeletal or tendinous anomalies in the upper limbs of AF children and to assess their functional consequences.
To determine if these upper limbs abnormalities could influence the somatosensory map of this part of the body in the cerebral cortex.
Secondary Evaluation Criteria :
MRI of the hand and forearm, orthopedic examination and functional assessment
Previously obtained brain MRI data
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fanconi Anemia
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Minor patients with Fanconi anemia
Arm Type
Experimental
Arm Description
MRI of hands and forearm, neuropsychological and neuromotor tests
Arm Title
Minor controls
Arm Type
Active Comparator
Arm Description
MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation
Intervention Type
Radiation
Intervention Name(s)
MRI of the hand and forearm,
Intervention Description
MRI of the hand and forearm,
Primary Outcome Measure Information:
Title
measurement of fine motor praxia
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with Fanconi Anemia defined according to two of the following diagnostic criteria already included in the MicroFanc study:
Chromosome breakage test after exposure to an alkylating agent (mitomycin) on peripheral blood lymphocytes.
FancD2 test on lymphocytes or fibroblasts
sensitivity of fibroblasts to mitomycin
mutation in one of the FANC complementation genes (A, B, C, D1, D2, E, F, G, I, J, L, M, N)
Non-transplanted patients or patients at a distance from CSH transplant (>3 years)
Age ≥5 years of age at inclusion (minimum age of accessibility for neuropsychological tests and no need for sedation for MRI)
Exclusion Criteria:
Subjects for whom both parents have not agreed to participate in the research, or for whom MRI is contraindicated.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sandrine Passemard, MD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Robert Drbré Hospital
City
Paris
ZIP/Postal Code
75019
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Microcephaly, Fanconi Anemia and Praxial Disorders
We'll reach out to this number within 24 hrs